藥品參考
Cemiplimab
Cemiplimab is a medicine in the class oncology. It is used for non-small cell lung cancer.
- 藥物類別: Oncology
- 用途: non-small cell lung cancer
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01XC33
- 常見劑型
- 注射劑
- 常見規格
- 50 mg/ml
- 已知交互作用
- 4 (中度: 3 · 輕微: 1)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
Recombinant human IgG4 monoclonal antibody that binds PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
成人常用劑量（仿單摘要）
Metastatic or locally advanced CSCC: 350 mg IV infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm: PD-1 blockade can disrupt immune tolerance to the fetus and raise the risk of pregnancy loss; IgG4 crosses the placenta. Check pregnancy status; use effective contraception during treatment and for at least 4 months after the last dose.
- 哺乳
- Unsafe No data on milk levels. Do not breastfeed during treatment and for at least 4 months after the last dose.
已通報的副作用
- Fatigue
- Musculoskeletal pain
- Rash
- Diarrhea
- Anemia
- Pruritus
禁忌症
- None.
哪些人需要特別留意
- Severe and fatal immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic reactions, nephritis, transplant rejection) can occur in any organ; evaluate liver enzymes, creatinine and thyroid function at baseline and periodically.
- Infusion-related reactions: interrupt, slow infusion, or permanently discontinue based on severity.
- Fatal and other serious complications can occur in patients receiving allogeneic HSCT before or after PD-1/PD-L1 blocking antibody.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (4)
- Cemiplimab + Piperacillin Moderate
- Cemiplimab + Piperacillin-tazobactam Moderate
- Cemiplimab + Siponimod Moderate
- Cemiplimab + Penicillin g Minor
同類別的其他藥品
常見問題
What is Cemiplimab used for?
Cemiplimab is a medicine in the class oncology. It is used for Non-small cell lung cancer, Squamous cell carcinoma.
What side effects have been reported with Cemiplimab?
Fatigue, Musculoskeletal pain, Rash, Diarrhea, Anemia, Pruritus.
Can Cemiplimab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: PD-1 blockade can disrupt immune tolerance to the fetus and raise the risk of pregnancy loss; IgG4 crosses the placenta. Check pregnancy status; use effective contraception during treatment and for at least 4 months after the last dose. Breastfeeding: Unsafe. No data on milk levels. Do not breastfeed during treatment and for at least 4 months after the last dose.
What does Cemiplimab interact with?
MediHelp lists 4 known interactions for Cemiplimab. Moderate: 3 · Minor: 1. The most serious include Piperacillin, Piperacillin-tazobactam, Siponimod.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
